UY37935A - Inhibidores de tirosina quinasas de la familia de los egfr mutantes - Google Patents

Inhibidores de tirosina quinasas de la familia de los egfr mutantes

Info

Publication number
UY37935A
UY37935A UY0001037935A UY37935A UY37935A UY 37935 A UY37935 A UY 37935A UY 0001037935 A UY0001037935 A UY 0001037935A UY 37935 A UY37935 A UY 37935A UY 37935 A UY37935 A UY 37935A
Authority
UY
Uruguay
Prior art keywords
family
inhibitors
tyrosine kinases
egfr mutants
egfr
Prior art date
Application number
UY0001037935A
Other languages
English (en)
Inventor
V Chaturvedula Prasad
Prasad Kolli
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of UY37935A publication Critical patent/UY37935A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un inhibidor de tirosina quinasa de la familia del receptor de factor de crecimiento epidérmico (EGFR) que comprende un grupo funcional que se puede unir al residuo de serina S797 en EGFR , que tiene una mutación C797S o el residuo de serina S805 en HER2 que tiene una mutación C805S.
UY0001037935A 2017-10-18 2018-10-17 Inhibidores de tirosina quinasas de la familia de los egfr mutantes UY37935A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762574110P 2017-10-18 2017-10-18

Publications (1)

Publication Number Publication Date
UY37935A true UY37935A (es) 2020-03-31

Family

ID=66174232

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037935A UY37935A (es) 2017-10-18 2018-10-17 Inhibidores de tirosina quinasas de la familia de los egfr mutantes

Country Status (17)

Country Link
US (2) US20200261455A1 (es)
EP (1) EP3697416A4 (es)
JP (1) JP2021500350A (es)
KR (1) KR20200072498A (es)
CN (1) CN111542322A (es)
AR (1) AR113451A1 (es)
AU (1) AU2018353142A1 (es)
BR (1) BR112020007783A2 (es)
CA (1) CA3078654A1 (es)
IL (1) IL274015A (es)
MX (1) MX2020004036A (es)
PH (1) PH12020550259A1 (es)
RU (1) RU2020117315A (es)
SG (1) SG11202003307XA (es)
TW (1) TW201922726A (es)
UY (1) UY37935A (es)
WO (1) WO2019079599A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210066841A (ko) * 2018-09-21 2021-06-07 스펙트럼 파마슈티컬즈 인크 신규한 퀴나졸린 egfr 억제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207323D0 (en) * 2002-03-28 2002-05-08 Astrazeneca Ab Compounds
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
CN1882573A (zh) * 2003-09-16 2006-12-20 阿斯利康(瑞典)有限公司 作为酪氨酸激酶抑制剂的喹唑啉衍生物
GB0321620D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
CN102482277B (zh) * 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
SI3157916T1 (sl) * 2014-06-19 2019-05-31 Ariad Pharmaceuticals, Inc. Heteroarilne spojine za zaviranja kinaze
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도

Also Published As

Publication number Publication date
AR113451A1 (es) 2020-05-06
EP3697416A1 (en) 2020-08-26
KR20200072498A (ko) 2020-06-22
SG11202003307XA (en) 2020-05-28
EP3697416A4 (en) 2021-06-02
US20230106731A1 (en) 2023-04-06
AU2018353142A1 (en) 2020-05-07
PH12020550259A1 (en) 2021-03-01
BR112020007783A2 (pt) 2020-10-20
RU2020117315A3 (es) 2022-04-25
TW201922726A (zh) 2019-06-16
US20200261455A1 (en) 2020-08-20
JP2021500350A (ja) 2021-01-07
MX2020004036A (es) 2021-01-15
IL274015A (en) 2020-06-30
CA3078654A1 (en) 2019-04-25
RU2020117315A (ru) 2021-11-17
WO2019079599A1 (en) 2019-04-25
CN111542322A (zh) 2020-08-14
WO2019079599A8 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CY1124422T1 (el) Ενωσεις πυραζολιου και μεθοδος για την παρασκευη και χρηση των ενωσεων
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
BR112018071184A2 (pt) inibidores do receptor de activina tipo quinase
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
CL2018003527A1 (es) Conjugados de anticuerpo anti-egfr y fármaco.
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
BR112017025986A2 (pt) inibidores de tirosina quinase de bruton.
EA201591420A1 (ru) Гетероарильные соединения и их применение
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
MX2018002217A (es) Nuevos compuestos biciclicos como inhibidores de autotaxina (atx).
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
JOP20210304A1 (ar) علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
KR20220035925A (ko) Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114